Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum W
DAK-Gesundheit awarded a contract of undisclosed value to Celltrion Healthcare Deutschland GmbH for Healthcare & Medical in March 2025 — one of 389 awards this buyer has made.
Buying agency
DAK-GesundheitWinning supplier
Celltrion Healthcare Deutschland GmbHContract description
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Ustekinumab, ATC L04AC05 (OBO) für die Zeit 01.08.2024 - 31.07.2025 (zzgl. Verlängerungsoption 1x12 Monate)
Related awards · DAK-Gesundheit
389 awardsThe buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.
- ocds-ted-210283-2024Aktivital GmbH€9.1M10 Apr 2024 Healthcare
- ocds-ted-211590-2024Kraaibeek GmbH€2.5M10 Apr 2024 Healthcare
- ocds-ted-828775-2025news aktuell GmbH€38.0K12 Dec 2025 IT
Premium · full dataset
See the full award context.
Competing bids, award margins and every related contract for DAK-Gesundheit and Celltrion Healthcare Deutschland GmbH — one subscription unlocks everything.
Sign Up Free →Free account · cancel anytime · 14-day money-back